Drug Trial Radar · NCT04425993
Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP Prevention
Last checked: Nov 20, 2026Latest source record: Oct 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,700
Actual
Start
Jul 1, 2020
Primary completion
May 30, 2022
Study completion Dec 30, 2022
Sponsor
- Lead sponsor
- Air Force Military Medical University, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 11, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) are at risk for post-ERCP pancreatitis (PEP), which is associated with adverse outcomes. Combination prophylaxis strategies are increasingly investigated to prevent PEP more effectively, and studies have confirmed the benefits. Two randomized controlled trials revealed that combination prophylaxis with rectal NSAIDs and sublingual nitrate has reduced PEP rates to 5.6%-6.7% in average-risk patients. However, there was concern regarding the safety of sublingual nitrate with reports of significant increasing the risk of hypotesion (rate of 54.9%) and headache (rate of 4.1%) as compared with placebo. As a safety drug, rectal administration of one dose NSAIDs is recommended as basic chemoprophylaxis in common or high-risk patients in guidelines. Results from previous studies showed rectal administration of NSAIDs significantly reduced PEP rate to 4-5.3% in average-risk patients. Although the difference in demographics, study design and outcomes definition, evidence was obtained that rectal NSAIDS was associated with similar PEP rate as combination prophylaxis with rectal NSAIDs and sublingual nitrate. However, evidence is lacking from large, randomized clinical trials indicating that efficiency of PEP prevention with rectal NSAIDs alone is not inferior to with combination prophylaxis. The investigators conduct this trial to investigate the hypothesis that rectal NSAIDs alone is non-inferior to the combination prophylaxis in terms of PEP prevention, but with reduce side effect.
Conditions
- Post-ERCP Acute Pancreatitis
Interventions
Isosorbide Dinitrate 5 MGDrug
All patients without contraindications should receive sublingual isosorbide dinitrate tablet within 5 minutes before ERCP.
Indomethacin 100 MGDrug
All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.
Sublingual PlaceboDrug
All patients without contraindications should receive sublingual placebo within 5 minutes before ERCP.
Rectal placeboDrug
All patients without contraindications should receive rectal placebo within 30 min before ERCP.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of post-ERCP PancreatitisTime frame: 14 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Xiamen Humanity Hospital
Xiamen, Fujian, China
Lanzhou University Second Hospital
Lanzhou, Gansu, China
Xi'an Central Hospital
Xi'an, Shaanxi, China
Xijing Hoapital
Xi'an, Shaanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.